Compare · EVGN vs MOS
EVGN vs MOS
Side-by-side comparison of Evogene Ltd (EVGN) and Mosaic Company (MOS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EVGN and MOS operate in Agricultural Chemicals (Industrials), so they compete in similar markets.
- MOS is the larger of the two at $7.07B, about 1096.7x EVGN ($6.4M).
- Over the past year, EVGN is down 43.2% and MOS is down 36.0% - MOS leads by 7.2 points.
- MOS has been more active in the news (16 items in the past 4 weeks vs 6 for EVGN).
- MOS has more recent analyst coverage (25 ratings vs 4 for EVGN).
- Company
- Evogene Ltd
- Mosaic Company
- Price
- $0.61-3.48%
- $22.25-2.88%
- Market cap
- $6.4M
- $7.07B
- 1M return
- -20.32%
- -5.56%
- 1Y return
- -43.19%
- -36.00%
- Industry
- Agricultural Chemicals
- Agricultural Chemicals
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 6
- 16
- Recent ratings
- 4
- 25
Evogene Ltd
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd., a subsidiary of Tikun Olam-Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
Mosaic Company
The Mosaic Company, through its subsidiaries, produces and markets concentrated phosphate and potash crop nutrients in North America and internationally. The company operates through three segments: Phosphates, Potash, and Mosaic Fertilizantes. It owns and operates mines, which produce concentrated phosphate crop nutrients, such as diammonium phosphate, monoammonium phosphate, and ammoniated phosphate products; and phosphate-based animal feed ingredients primarily under the Biofos and Nexfos brand names, as well as produces a double sulfate of potash magnesia product under K-Mag brand name. The company also produces and sells potash for use in the manufacturing of mixed crop nutrients and animal feed ingredients, and for industrial use; and for use in the de-icing and as a water softener regenerant. In addition, it provides nitrogen-based crop nutrients and animal feed ingredients, and other ancillary services; and purchases and sells phosphates, potash, and nitrogen products. The company sells its products to wholesale distributors, retail chains, farmers, cooperatives, independent retailers, and national accounts. The Mosaic Company was incorporated in 2004 and is headquartered in Tampa, Florida.
Latest EVGN
- Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica
- SEC Form 424B3 filed by Evogene Ltd
- SEC Form 6-K filed by Evogene Ltd
- Evogene Reports First Quarter 2026 Financial Results
- SEC Form 6-K filed by Evogene Ltd
- Evogene to Present at the 24th Schrödinger European User Group Meeting
- Evogene Schedules First Quarter 2026 Financial Results Release
- SEC Form EFFECT filed by Evogene Ltd
- SEC Form 3 filed by new insider Ravzin Polina
- SEC Form EFFECT filed by Evogene Ltd
Latest MOS
- Director Kuzenko Jody Lynne converted options into 4,873 shares, increasing direct ownership by 57% to 13,444 units (SEC Form 4)
- Director Gitzel Timothy S. converted options into 4,873 shares, increasing direct ownership by 7% to 79,527 units (SEC Form 4)
- Director Shanahan Kathleen M converted options into 4,873 shares, increasing direct ownership by 202% to 7,286 units (SEC Form 4)
- Director Watkins Gretchen H converted options into 4,873 shares, increasing direct ownership by 16% to 35,934 units (SEC Form 4)
- Director Koenig Emery N. converted options into 4,873 shares, increasing direct ownership by 6% to 86,228 units (SEC Form 4)
- Director Teixeira Joao Roberto Goncalves converted options into 4,873 shares, increasing direct ownership by 57% to 13,442 units (SEC Form 4)
- Director Beebe Cheryl K converted options into 2,437 shares, increasing direct ownership by 6% to 46,691 units (SEC Form 4)
- Director Seaton David Thomas converted options into 3,167 shares, increasing direct ownership by 7% to 51,089 units (SEC Form 4)
- Director Ebel Gregory L converted options into 7,310 shares (SEC Form 4)
- Director Westbrook Kelvin R converted options into 2,437 shares, increasing direct ownership by 7% to 39,807 units (SEC Form 4)